ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancreatic Adenocarcinoma
- PMID: 35583695
- DOI: 10.1245/s10434-022-11878-6
ASO Author Reflections: The Impact on Survival of Downstaging by Neoadjuvant Chemotherapy or Chemoradiotherapy in Pancreatic Adenocarcinoma
Comment on
-
Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival.Ann Surg Oncol. 2022 Sep;29(9):6015-6028. doi: 10.1245/s10434-022-11800-0. Epub 2022 May 18. Ann Surg Oncol. 2022. PMID: 35583691
Similar articles
-
Downstaging of Pancreatic Adenocarcinoma With Either Neoadjuvant Chemotherapy or Chemoradiotherapy Improves Survival.Ann Surg Oncol. 2022 Sep;29(9):6015-6028. doi: 10.1245/s10434-022-11800-0. Epub 2022 May 18. Ann Surg Oncol. 2022. PMID: 35583691
-
ASO Author Reflections: Neoadjuvant Chemotherapy for Pancreatic Adenocarcinoma Lessens the Deleterious Effect of Omission of Adjuvant Chemotherapy.Ann Surg Oncol. 2021 Jul;28(7):3808-3809. doi: 10.1245/s10434-020-09487-2. Epub 2021 Jan 21. Ann Surg Oncol. 2021. PMID: 33475885 No abstract available.
-
Nodal downstaging as a treatment goal for node-positive pancreatic cancer.Surgery. 2019 Jun;165(6):1144-1150. doi: 10.1016/j.surg.2018.12.009. Epub 2019 Feb 10. Surgery. 2019. PMID: 30745009
-
Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma.Jpn J Clin Oncol. 2020 May 5;50(5):483-489. doi: 10.1093/jjco/hyaa018. Jpn J Clin Oncol. 2020. PMID: 32083290 Review.
-
Does neoadjuvant therapy for pancreatic head adenocarcinoma increase postoperative morbidity? A systematic review of the literature with meta-analysis.J Surg Oncol. 2020 Apr;121(5):881-892. doi: 10.1002/jso.25851. Epub 2020 Jan 28. J Surg Oncol. 2020. PMID: 31994193
Cited by
-
ASO Author Reflections: Patient-Reported Outcomes for Breast Reconstruction Clinical Practice.Ann Surg Oncol. 2022 Aug;29(8):5294-5295. doi: 10.1245/s10434-022-11527-y. Epub 2022 Mar 18. Ann Surg Oncol. 2022. PMID: 35303179 Free PMC article. No abstract available.
References
-
- Sugimoto M, Takahashi N, Farnell MB, et al. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: a propensity matching and intention-to-treat analysis. J Surg Oncol. 2019;120(6):976–84. https://doi.org/10.1002/jso.25681 . - DOI - PubMed
-
- Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763–73. https://doi.org/10.1200/JCO.19.02274 . - DOI - PubMed - PMC
-
- Hu Q, Wang D, Chen Y, Li X, Cao P, Cao D. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma. Radiat Oncol. 2019;14(1):120. https://doi.org/10.1186/s13014-019-1330-0 . - DOI - PubMed - PMC
-
- O’Shea AE, Kemp Bohan PM, Carpenter EL, et al. Downstaging of pancreatic adenocarcinoma with either neoadjuvant chemotherapy or chemoradiotherapy improves survival. Ann Surg Onocol. 2022. https://doi.org/10.1245/s10434-022-11800-0 . - DOI
-
- Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. J Clin Oncol. 2021;39(3_suppl):377–377. https://doi.org/10.1200/JCO.2021.39.3_suppl.377 . - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical